FARSA Antibody

Proteintech FARSA Polyclonal Antibody (18121-1-AP)

• Host/Isotype: Rabbit IgG

• Applications:

  Application	Dilution Range	Validated Samples
  WB	1:4,000–1:16,000	HeLa, MCF-7, HepG2 cells
  IHC	1:500–1:2,000	Human liver/kidney cancer tissue
  IF/ICC	1:200–1:800	MCF-7, HeLa cells
  IP	0.5–4.0 µg/1–3 mg lysate	MCF-7 cells

• Molecular Weight: Observed at 57 kDa (calculated 58 kDa) .

• Storage: Stable at -20°C in PBS with 50% glycerol and 0.02% sodium azide .

Assay Genie FARSA Rabbit Polyclonal Antibody (CAB15670)

• Host/Isotype: Rabbit IgG

• Applications:

  Application	Dilution Range	Validated Samples
  WB	1:500–1:2,000	HeLa, mouse liver
  ELISA	Not specified	Human samples

• Immunogen: Recombinant protein spanning amino acids 210–486 of human FARSA .

• Storage: PBS with 0.01% thimerosal and 50% glycerol (pH 7.3) .

Role in Mantle Cell Lymphoma (MCL)

• Expression Patterns: Lower FARSA levels correlate with chemoresistance in MCL cell lines (e.g., REC1, Mino vs. BTZ-sensitive Jeko) .

• Functional Impact:

  • Knockdown: Accelerates cell proliferation and S-phase entry but does not induce apoptosis .

  • Overexpression: Triggers cell-cycle arrest and apoptosis via PI3K-AKT/FOXO1-RAG1 pathways .

Key Validated Use Cases

• Western Blot: Detects FARSA in lysates from HeLa, K-562, and MCF-7 cells .

• Immunohistochemistry: Localizes FARSA in liver/kidney cancer tissues with antigen retrieval (TE buffer pH 9.0 recommended) .

• Functional Studies: Used to explore FARSA's noncanonical roles in cell-cycle regulation and survival .

Technical Considerations

• Cross-Reactivity: Confirmed in human, mouse, and rat samples .

• Controls: Include FARSA-overexpressing or knockdown cell lines (e.g., Jeko MCL models) for functional assays .

Future Directions

• Therapeutic Targeting: FARSA’s dual role in protein synthesis and cell-cycle regulation highlights its potential as a biomarker for drug resistance in cancers like MCL .

• Antibody Optimization: Engineering Fc domains to enhance effector functions (e.g., phagocytosis) could improve therapeutic utility, as seen in antiviral antibody research .